Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Insulet produces and sells Omnipod, an automated insulin delivery device, which works without the external tubing required by conventional pumps and eliminates the need for multiple daily ...

From wearable glucose monitors to AI-driven health insights, recent advances are giving patients new ways to manage blood ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop ...

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...

PLYMOUTH MEETING, Pa. – AdaptHealth CEO Suzanne Foster is doubling down on efforts to turn around the company’s struggling diabetes business, saying it was “worse” than she initially thought it was.